Results 131 to 140 of about 1,906,831 (271)

First‐in‐Human Study of a Long‐Acting GLP‐1 Receptor Agonist (TE‐8105) in Overweight or Obese Adults Without Type 2 Diabetes Mellitus

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have revolutionized weight management and are becoming essential for the treatment of obesity‐related medical conditions. This study aimed to determine the pharmacokinetics, preliminary pharmacodynamics, safety, and tolerability of a long‐acting GLP‐1 receptor agonist, TE‐8105, in overweight or
Ya‐Shan Chuang   +7 more
wiley   +1 more source

Itching for a diagnosis: Dysesthesias as an atypical presentation of Wilson disease in an adolescent—Case report

open access: yesJPGN Reports, Volume 7, Issue 3, Page 383-386, August 2026.
Abstract Wilson disease (WD) is an autosomal recessive disorder of hepatic copper metabolism with varied clinical presentations. We describe a 15‐year‐old male referred for elevated aminotransferases, burning facial pruritis, scalp dysesthesias, and chronic bilateral lower extremity edema.
Tierra L. R. Mosher   +2 more
wiley   +1 more source

Reductive dominance and limited cytochrome P450 activity in neonicotinoid metabolism by elephant liver microsomes. [PDF]

open access: yesJ Vet Med Sci
Watanabe K   +12 more
europepmc   +1 more source

Could NAPQI Contribute to Paracetamol Analgesia? Redox Modulation of Kv7 Ion Channels

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Paracetamol (acetaminophen, APAP) is one of the most widely used analgesic and antipyretic drugs worldwide, yet its mechanism of action remains incompletely understood. While several pathways have been proposed, including cyclooxygenase inhibition and endocannabinoid modulation via AM404, none fully account for its pharmacological profile. The
Sara M‐Alicante   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy